Navigation Links
QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
Date:3/31/2009

tment period. All women are also being supplied with a non-hormonal vaginal lubricant to be applied as needed during the treatment period. The co-primary endpoints of the study are the change from baseline to week 12 in the percentage of parabasal cells in the vaginal maturation index, the percentage of superficial cells in the vaginal maturation index, vaginal pH, and improvements in the most bothersome moderate to severe vulvovaginal atrophy symptoms of vaginal dryness and dyspareunia.

The study is the second pivotal Phase 3 clinical trial for Ophena(TM), a novel selective estrogen receptor modulator (SERM) for the treatment of vaginal atrophy. Vaginal atrophy is a common condition in postmenopausal women characterized by progressive long-term vaginal symptoms such as dryness, irritation and sexual pain (dyspareunia). The first Phase 3 trial for Ophena(TM) met all the co-primary endpoints at the 60mg dosage, with statistically significant improvements in vaginal dryness and dyspareunia, as well as statistically significant improvement in the proportion of parabasal and superficial cells in the epithelium of vaginal walls and a decline in vaginal pH levels.

About Postmenopausal Vaginal Atrophy

Postmenopausal vaginal atrophy is a chronic and progressive condition characterized by symptoms including vaginal dryness, sexual pain (dyspareunia) and irritation. Declining estrogen levels during menopause can cause tissues of the vaginal lining to grow thinner and to lose elasticity, a condition known as vaginal atrophy. Dryness and irritation associated with reductions in vaginal secretions often cause pain or bleeding during sexual intercourse. It is estimated that 45-75 percent of postmenopausal women experience chronic symptoms of vaginal atrophy which are bothersome in over 90 percent of cases. Current prescription treatments approved for this condition all contain estrogen, administered either orally or
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
5. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
6. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013  Actavis, Inc. (NYSE: ... filed with the U.S. Securities and Exchange Commission (SEC) a ... acquisition of Warner Chilcott plc (NASDAQ: ... and Warner Chilcott (the "Form S-4"). ... Warner Chilcott have entered into a definitive agreement pursuant ...
(Date:6/18/2013)... N.C. , June 18, 2013  Recent regulatory ... difficult for Medical Education groups at large pharmaceutical companies ... the safe and effective use of their new products. ... pharma industry, it is crucial that these "Med ... healthcare professionals. To address the changes that ...
(Date:6/18/2013)... 18, 2013  Cataracts are the leading cause of ... of Ophthalmology, aging is the leading cause of eye ... natural lens. 22 million Americans age 40 and older ... to age, that number will increase over 30 million. ... iPads, smart-phones and computers, the demographic of ages 40 ...
Breaking Medicine Technology:Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3
... 2011 MediSapiens Ltd , a Finnish ... gene expression yet for public use. The data is available ... home page of MediSapiens Ltd , allowing exploration of ... healthy human tissues. Since the sequencing of the human genome, ...
... SAN CARLOS, Calif. and SAN DIEGO, Sept. 29, 2011 ... maternal and fetal health, today announced it has signed ... developer and manufacturer of life sciences tools for the ... Under the terms of the agreement, Verinata Health will ...
Cached Medicine Technology:Transcriptome Viewer - Comprehensive Genome-wide Map of Human Gene Expression Activity Released for Public by MediSapiens 2Verinata Health Announces a Multi-Year Supply Agreement with Illumina in the Field of Non-Invasive Prenatal Diagnostics 2
(Date:6/18/2013)... have discovered and mapped the signaling network between two ... could cut off cancer cell growth at its starting ... University of Texas MD Anderson Cancer Center reported the ... cancer drug target, and MCM7, a protein vital to ... issue of Cancer Cell . , "MCM7 overexpression ...
(Date:6/18/2013)... Two months ago, Suyima Torres, 28, died ... second session of a silicone treatment for gluteus augmentation at ... allegedly performed by a mystery Venezuelan doctor in a center ... Dr. Bernabe Vazquez of Bayshore Cosmetic Surgery , women ... who are not board certified is more common than people ...
(Date:6/18/2013)... June 18, 2013 David Connett, DO, ... Family Medicine for the College of Osteopathic Medicine of ... has been elected president of the Osteopathic Medical ... Brown Jr. appointed Connett, a 1984 alumnus of COMP, ... recently elected Connett to the position during a conference ...
(Date:6/18/2013)... keep their scheduled medical appointments and their disease ... explains things clearly and knows them as a person, ... , "If people feel their doctor really knows them ... their best interests at heart and may be more ... E. Flickinger, M.D., M.P.H., a fellow in the Division ...
(Date:6/18/2013)... NEW YORK (June 18, 2013)-- An international team of ... a new framework for evidence-based surgery and device research, ... used in evidence-based medicine. , "Currently, there is no ... that don,t offer any benefits to patients or may ... of Weill Cornell Medical College. , In the ...
Breaking Medicine News(10 mins):Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 2Health News:Dr. Bernabe Vazquez Speaks on Miami Woman’s Deadly Silicone Butt Injection 3Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Tackling a framework for surgical innovation 2Health News:Tackling a framework for surgical innovation 3
... (Feb. 9, 2011) - The population of aged persons worldwide ... there are many different diseases that affect the minds of ... new ground in the ongoing project of identifying and defining ... Peter Nelson of the University of Kentucky Sanders-Brown Center on ...
... almost 40 other countries, scientists are reporting the development of ... to detect the toxin that causes the disease. The report ... more than 200,000 people annually, mainly in developing countries, and ... elderly. J. Manuel Perez and colleagues note that cholera ...
... of Medicine postdoctoral fellows recently were awarded fellowships. Rita ... Cancer Research Foundation fellowships, and Bagrat Abazyan, M.D., Robert ... Kim, Ph.D., M.D., Ph.D., Minae Niwa, Ph.D., Frederick Charles ... Ph.D., were among the 214 recipients of the NARSAD: ...
... Feb. 8 (HealthDay News) -- Removing many lymph nodes may not ... a lumpectomy to remove the mass, followed by radiation. Researchers ... the American Medical Association found that just removing one or ... spreads first -- allows women to live just as long as ...
... Motorcycle helmets, long known to dramatically reduce the number of ... associated with a lower risk of cervical spine injury, new ... popular myth that wearing a helmet while riding a motorcycle ... Adil H. Haider, M.D., M.P.H., an assistant professor of surgery ...
... that many patients realise that diabetes can affect their kidneys ... a multi-cultural study in the March issue of the ... spoke to 48 patients with diabetes attending specialist renal services ... kidney risks posed by the disease was very low. ...
Cached Medicine News:Health News:Beyond Alzheimer's: Research explores hippocampal sclerosis 2Health News:Johns Hopkins School of Medicine postdoctoral fellows win awards 2Health News:Removing Many Lymph Nodes in Early Breast Cancer Not Always Needed: Study 2Health News:Removing Many Lymph Nodes in Early Breast Cancer Not Always Needed: Study 3Health News:Motorcycle helmets reduce spine injuries after collisions 2Health News:Experts call for greater awareness of the links between diabetes and kidney disease 2Health News:Experts call for greater awareness of the links between diabetes and kidney disease 3
Adult size. Clear plastic. Accommodates either eye. Packaged 12 per box. Available in either adult or pediatric size....
... Flow rate: 45 ... micron. For filtering fluids ... in table; bi-directional membrane ... kg/cm2 (75 psi) via ...
Straight, right side cutting, 1.5 mm x 4 mm bite, length of shaft 115 mm, overall length 6.3 inches....
20 mm. Plastic, methylmethacrylate. Supplied sterile....
Medicine Products: